Health Catalyst’s (HCAT) “Overweight” Rating Reiterated at Piper Sandler

Health Catalyst (NASDAQ:HCAT)‘s stock had its “overweight” rating reiterated by analysts at Piper Sandler in a report issued on Tuesday,Benzinga reports. They presently have a $12.00 price objective on the stock, up from their previous price objective of $11.00. Piper Sandler’s price target would suggest a potential upside of 40.85% from the company’s previous close.

A number of other equities research analysts also recently weighed in on HCAT. Evercore ISI upped their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. JPMorgan Chase & Co. increased their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a report on Friday, October 4th. Stephens upped their price target on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Finally, Citigroup raised their price objective on Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.79.

Health Catalyst Price Performance

Shares of NASDAQ:HCAT opened at $8.52 on Tuesday. The stock has a market cap of $518.44 million, a price-to-earnings ratio of -6.31 and a beta of 1.32. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst has a 12 month low of $5.42 and a 12 month high of $11.41. The stock’s 50 day moving average price is $8.13 and its 200 day moving average price is $7.28.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The firm had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. During the same period in the prior year, the firm posted ($0.22) EPS. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. Equities research analysts anticipate that Health Catalyst will post -0.35 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the transaction, the insider now directly owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This trade represents a 2.85 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Daniel Lesueur sold 5,209 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $7.70, for a total value of $40,109.30. Following the completion of the sale, the chief operating officer now owns 129,690 shares of the company’s stock, valued at approximately $998,613. This trade represents a 3.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 34,068 shares of company stock valued at $257,555 over the last ninety days. Corporate insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

A number of institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. boosted its holdings in shares of Health Catalyst by 6.9% during the 2nd quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock worth $188,000 after buying an additional 1,907 shares during the period. Harbor Capital Advisors Inc. lifted its position in Health Catalyst by 21.3% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock worth $96,000 after acquiring an additional 2,064 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Health Catalyst by 10.3% during the second quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock valued at $148,000 after acquiring an additional 2,164 shares during the period. Creative Planning grew its position in shares of Health Catalyst by 13.2% in the third quarter. Creative Planning now owns 21,348 shares of the company’s stock valued at $174,000 after purchasing an additional 2,486 shares during the last quarter. Finally, Quarry LP increased its stake in shares of Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after purchasing an additional 2,610 shares during the period. Institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.